Allmed Medical Products Co., Ltd
SZSE:002950.SZ
9.17 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 3,326.292 | 2,756.665 | 4,210.503 | 2,925.555 | 3,834.498 | 2,352.462 | 2,027.512 | 1,711.116 | 1,558.085 | 1,585.174 | 1,509.026 |
| Cost of Revenue
| 2,368.862 | 2,098.733 | 2,793.85 | 2,044.052 | 2,234.873 | 1,555.343 | 1,391.237 | 1,130.683 | 1,002.572 | 1,058.948 | 1,009.41 |
| Gross Profit
| 957.43 | 657.932 | 1,416.653 | 881.503 | 1,599.625 | 797.119 | 636.275 | 580.433 | 555.513 | 526.226 | 499.616 |
| Gross Profit Ratio
| 0.288 | 0.239 | 0.336 | 0.301 | 0.417 | 0.339 | 0.314 | 0.339 | 0.357 | 0.332 | 0.331 |
| Reseach & Development Expenses
| 106.37 | 77.366 | 107.735 | 94.578 | 118.127 | 59.713 | 49.739 | 45.412 | 38.375 | 34.387 | 0 |
| General & Administrative Expenses
| 53.562 | 59.356 | 98.639 | 66.183 | 51.884 | 62.068 | 38.992 | 30.43 | 23.934 | 19.553 | 162.99 |
| Selling & Marketing Expenses
| -48.96 | 33.594 | 83.796 | 74.472 | 38.205 | 130.114 | 112.869 | 88.498 | 75.304 | 78.264 | 69.073 |
| SG&A
| 4.602 | 386.075 | 182.435 | 140.654 | 90.088 | 192.182 | 151.862 | 118.928 | 99.238 | 97.817 | 232.063 |
| Other Expenses
| 387.993 | 25.433 | 248.928 | 188.006 | 145.423 | 129.72 | -1.21 | 34.215 | 56.848 | -37.921 | 32.169 |
| Operating Expenses
| 498.965 | 488.875 | 539.097 | 423.239 | 353.638 | 381.615 | 320.687 | 300.288 | 258.381 | 253.296 | 243.886 |
| Operating Income
| 458.465 | 169.057 | 525.072 | 505.875 | 1,341.781 | 390.544 | 277.595 | 283.494 | 284.293 | 169.324 | 199.919 |
| Operating Income Ratio
| 0.138 | 0.061 | 0.125 | 0.173 | 0.35 | 0.166 | 0.137 | 0.166 | 0.182 | 0.107 | 0.132 |
| Total Other Income Expenses Net
| -4.073 | -0.016 | -40.168 | -0.384 | -3.117 | 3.612 | -1.21 | -1.206 | 9.306 | -82.417 | 31.898 |
| Income Before Tax
| 454.391 | 169.042 | 484.905 | 505.491 | 1,338.664 | 394.156 | 276.384 | 282.288 | 293.599 | 188.134 | 231.817 |
| Income Before Tax Ratio
| 0.137 | 0.061 | 0.115 | 0.173 | 0.349 | 0.168 | 0.136 | 0.165 | 0.188 | 0.119 | 0.154 |
| Income Tax Expense
| 85.595 | 64.825 | 80.256 | 73.53 | 178.202 | 69.958 | 50.074 | 48.981 | 45.481 | 35.535 | 39.351 |
| Net Income
| 368.679 | 110.4 | 406.792 | 431.215 | 1,157.527 | 325.812 | 227.781 | 233.733 | 248.134 | 156.98 | 198.425 |
| Net Income Ratio
| 0.111 | 0.04 | 0.097 | 0.147 | 0.302 | 0.138 | 0.112 | 0.137 | 0.159 | 0.099 | 0.131 |
| EPS
| 0.59 | 0.17 | 0.64 | 0.68 | 1.83 | 0.51 | 0.41 | 0.42 | 0.43 | 0.27 | 0.34 |
| EPS Diluted
| 0.59 | 0.17 | 0.64 | 0.68 | 1.83 | 0.51 | 0.41 | 0.42 | 0.43 | 0.27 | 0.34 |
| EBITDA
| 708.93 | 422.239 | 696.673 | 672.874 | 1,491.71 | 558.401 | 427.581 | 394.548 | 391.206 | 283.99 | 321.847 |
| EBITDA Ratio
| 0.213 | 0.153 | 0.165 | 0.23 | 0.389 | 0.237 | 0.211 | 0.231 | 0.251 | 0.179 | 0.213 |